Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.
Stölzel F, Wermke M, Röllig C, Thiede C, Platzbecker U, Bornhäuser M. Stölzel F, et al. Among authors: thiede c. Haematologica. 2010 Jan;95(1):171-2. doi: 10.3324/haematol.2009.016568. Epub 2009 Oct 8. Haematologica. 2010. PMID: 19815840 Free PMC article. No abstract available.
Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.
Hänel M, Thiede C, Helwig A, Prange-Krex G, Babatz J, Haack M, Kroschinsky F, Fetscher S, Ehninger G, Bornhäuser M. Hänel M, et al. Among authors: thiede c. Br J Haematol. 2003 Mar;120(6):1093-4. doi: 10.1046/j.1365-2141.2003.04208_4.x. Br J Haematol. 2003. PMID: 12648086 Free article. No abstract available.
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.
Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C; AML SHG 96 study group. Bornhäuser M, et al. Among authors: thiede c. Blood. 2007 Mar 1;109(5):2264-5; author reply 2265. doi: 10.1182/blood-2006-09-047225. Blood. 2007. PMID: 17312001 Free article. No abstract available.
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Bornhäuser M, et al. Among authors: thiede c. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894. Clin Cancer Res. 2008. PMID: 18765552 Clinical Trial.
368 results